For example, patients with hypertriglyceridemia commonly receive treatment of fibrates, a kind of PPARα agonists, and patients with T2DM often receive treatment of thiazolidinediones, a kind of PPARγ agonists that worked as insulin-sensitizers. The gene discussed is PPARA; the disease is type 2 diabetes mellitus.